title: Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
abstract: Antibody drug conjugates (ADCs) have recently been proven to be highly potent anti-tumor drugs, typically exceeding the efficacy of conventional monoclonal antibodies (mAbs). ADCs are currently produced by chemical conjugation of a small-molecule toxin to the mAb through lysine or cysteine side chains. This leads to heterogeneous mixtures of ADCs in which variable numbers of drugs are conjugated to individual antibodies and in which the site of conjugation cannot be defined. Consequently, there is currently significant interest in further development of drug conjugation technologies, with a particular focus on site-specific payload conjugation. Here, we present an enzymatic conjugation platform based on the S. aureus sortase A-mediated transpeptidation reaction, allowing the efficient generation of ADCs with toxins conjugated to pre-defined sites at pre-defined drug-to-antibody ratios. For this, two modifications were introduced: first, immunoglobulin heavy (IgH) and light (IgL) chains were modified at their C-termini by addition of the sortase A recognition motif LPETG, and second, the small molecule tubulin polymerization inhibitors monomethylauristatin E (MMAE) and maytansine were modified by addition of a pentaglycine peptide, thus making them suitable substrates for sortase A-mediated transpeptidation. We demonstrate efficient generation and characterization of the anti-CD30 ADC Ac10-vcPAB-MMAE, an enzymatically conjugated counterpart of brentuximab vedotin (Adcetris), as well as several anti-HER-2 ADCs including trastuzumab-maytansine, the counterpart of trastuzumab emtansine (Kadcyla). ADCs generated in this manner were found to display in vitro cell killing activities indistinguishable from the classic conjugates. Further, when tested in vivo in a HER-2-overexpressing ovarian cancer xenograft mouse model, enzymatically generated trastuzumab-maytansine was found to lead to complete regression of established tumors, similar to Kadcyla.
authors.affiliation: NBE-Therapeutics AG, Hochbergerstrasse, Basel, Switzerland.
authors.forename: Roger R
authors.initials: RR
authors.lastname: Beerli
authors.affiliation: NBE-Therapeutics AG, Hochbergerstrasse, Basel, Switzerland.
authors.forename: Tamara
authors.initials: T
authors.lastname: Hell
authors.affiliation: NBE-Therapeutics AG, Hochbergerstrasse, Basel, Switzerland.
authors.forename: Anna S
authors.initials: AS
authors.lastname: Merkel
authors.affiliation: NBE-Therapeutics AG, Hochbergerstrasse, Basel, Switzerland.
authors.forename: Ulf
authors.initials: U
authors.lastname: Grawunder
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D019881:Aminoacyltransferases / Q000737:chemistry* / Q000276:immunology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000737:chemistry* / Q000276:immunology; D000079963:Brentuximab Vedotin; D003546:Cysteine Endopeptidases / Q000737:chemistry* / Q000276:immunology; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology*; D017730:Ki-1 Antigen / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology; D008453:Maytansine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000276:immunology / Q000494:pharmacology; D051379:Mice; D008819:Mice, Nude; D009842:Oligopeptides / Q000737:chemistry / Q000276:immunology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D015202:Protein Engineering; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology; D013211:Staphylococcus aureus / Q000737:chemistry / Q000201:enzymology; D000068878:Trastuzumab; D023041:Xenograft Model Antitumor Assays
chemical_list: D000080044:Ado-Trastuzumab Emtansine; D019881:Aminoacyltransferases; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001426:Bacterial Proteins; D000079963:Brentuximab Vedotin; D003546:Cysteine Endopeptidases; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D008453:Maytansine; D009842:Oligopeptides; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C120542:sortase A; C508053:ERBB2 protein, human; C495575:monomethyl auristatin E